[Anticancer chemotherapy containing cisplatin in patients with lung cancer and kidney function].
To carry out safe anticancer chemotherapy one should consider the kidney function. Insufficiency of that main organ responsible for drugs excretion, caused either by neoplastic disease or by chemotherapy, can diminish the possibility or even make impossible of carrying out a complete treatment cycle. The aim of our work was to evaluate the kidney function in patients with lung cancer during anticancer chemotherapy containing cisplatin. The tubular function was studied by estimation the activity of N-acetyl-beta-D-glucosaminidase in urine and glomerular function was studied by estimation the concentration of creatinine in urine, urea, uric acid and electrolytes in plasma. The observations have recorded that neoplastic process, as well as chemotherapy impaired the tubular function. It has showed that it does exist a necessity of detailed estimation of kidney excretory function before, during and after the end of anticancer therapy. Determination of NAG activity in urine may be helpful for the recognition of the patients at high nephrotoxicity risk, who need special care.
Wiela-Hojeńska
Anna
A
Katedra i Zakład Farmakologii Klinicznej AM we Wrocławiu.
Passowicz-Muszyńska
Ewa
E
Orzechowska-Juzwenko
Krystyna
K
Jankowska
Renata
R
Hurkacz
Magdalena
M
Unolt
Józefa
J
Weryńska
Bozena
B
Gołecki
Marcin
M
Dyła
Tomasz
T
D000118:Acetylglucosaminidase / Q000378:metabolism; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D006801:Humans; D007668:Kidney / Q000378:metabolism / Q000503:physiopathology*; D007677:Kidney Function Tests; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*; D008875:Middle Aged
D000970:Antineoplastic Agents; D000118:Acetylglucosaminidase; D002945:Cisplatin